A roundup published on November 19, 2026, covered analyst calls across technology, insurance, healthcare and other sectors. The ratings and price targets below are the firms’ assessments, not reported outcomes.
Technology and AI
- Wolfe initiated coverage of Anthropic at outperform, calling it “best-in-class” and projecting substantial revenue growth by calendar year 2028.
- JPMorgan reiterated an overweight rating on Apple. It said its consumer survey found iPhone purchase intent at a five-year high, led by customers upgrading their phones, while interest among people switching brands moderated for a second consecutive year.
- UBS upgraded Box to buy from neutral, citing what it described as evidence that AI-driven workflows could accelerate growth. UBS also upgraded MongoDB to buy from neutral, saying it saw durable growth.
- Barclays initiated Synopsys at overweight, pointing to demand for electronic-design-automation tools and custom intellectual property.
- Daiwa reiterated an outperform rating on Nvidia but cut its price target to $185 from $245 per share. It raised questions about the durability of AI spending and future CEO succession while saying it did not believe revenue and earnings had peaked, provided customers continued to see returns from AI.
- Morgan Stanley reiterated an overweight rating associated with SpaceX, describing “SPCX” as a potential pick for an “Off-The-Grid” portfolio. The roundup did not explain the instrument represented by that ticker.
Insurance, healthcare and consumer companies
- StoneX initiated NXP Semiconductors and Harley-Davidson at buy. Its $40 price target for Harley-Davidson accompanied a turnaround thesis that included the expected return of entry-level bikes in fiscal 2027.
- Bank of America initiated Viridian Therapeutics at buy with a $47 price objective, citing its work in thyroid eye disease. Leerink upgraded Abbott Laboratories to outperform from market perform, saying its assessment of the risk-reward balance had improved.
- Piper Sandler initiated insurer Kingstone Companies at overweight with a $24 price target and Outlook Therapeutics at overweight with a $4 target. Wells Fargo upgraded Brown & Brown and Marsh & McLennan to overweight from equal weight.
- The roundup listed a UBS upgrade of Unum Group to buy from neutral, but its accompanying summary attributed the rationale to Piper. It also listed a UBS upgrade of Reinsurance Group of America to buy from neutral, with its target raised to $325 from $236.
- Barclays initiated seed company Vylor and retailer BBB Foods at overweight, assigning targets of $83 and $90, respectively. Rothschild & Co Redburn initiated online gambling operator Super Group at buy, citing its position in South Africa and potential growth elsewhere in Africa.
Other calls
- Citizens upgraded Expeditors International to market outperform from market perform with a $240 target, citing higher earnings-per-share expectations.
- Oppenheimer initiated drone-parts company Unusual Machines, radio-frequency detection company HawkEye 360 and defense-technology company Swarmer at outperform. Its respective 12- to 18-month price targets were $30, $30 and $20.
- BMO upgraded Bloom Energy to outperform from market perform but lowered its target to $230 from $260. B. Riley upgraded AST SpaceMobile to buy from hold, saying its assessment of the risk-reward balance had improved.
- Monness Crespi Hardt downgraded Strategy to sell from neutral. The firm linked its bearish view to bitcoin, the company’s leverage and the stock’s premium to its bitcoin holdings.
